CTU: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Zhang, Alison (Primary Chief Investigator)
Armstrong, Emilia (Clinical Trial Unit Staff)
Quinlan, Gabriel (Clinical Trial Unit Staff)
Delahunt Smoleniec, Jacqui (Clinical Trial Unit Staff)
Martin, Lewis (Clinical Trial Unit Staff)
Garcia, Michelle (Clinical Trial Unit Staff)
Lawrie, Angus (Clinical Trial Unit Staff)
Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Description

MK-2400-01A Substudy

Short title	MK-2400-01A
Status	Finished
Effective start/end date	17/06/25 → 2/05/26